JPRN-UMIN000011091
Completed
未知
Investigation of clinical efficacy for Aflibercept in patients with polypoidal choroidal vasculopathy (PCV) - Investigation of Eylea for PCV
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University0 sites50 target enrollmentJuly 2, 2013
ConditionsPolypoidal Choroidal Vasculopathy
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Polypoidal Choroidal Vasculopathy
- Sponsor
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Greatest Linear Dimension (GLD) of the total lesion area \<12 Macular Photocoagulation Study Disc Areas 2\) Presence of subretinal hemorrhage, scar or macular fibrosis (\>50% lesion area) 3\) Prior treatment with dexamethasone (\<6 months) or triamcinolone (\<30 days), intraocular surgery (\<3 months) 4\) Active intraocular inflammation 5\) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 6\) pregnant women and nursing mothers 7\) Patient who the doctor in charge judges are ineligible for the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Investigation of clinical efficacy of aflicbercept in patients with polypoidal choroidal vasculopathy (PCV) with resistance of ranibizumabPolypoidal choroidal vasculopathyJPRN-UMIN000012493Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo30
Recruiting
Phase 4
Prospective study evaluating aflibercept in patients with recurrent or prolonged diabetic macular edema after vitrectomyDiabetic macular edemaJPRN-UMIN000016036Kyushu university30
Active, not recruiting
Phase 1
Aflibercept Efficacy in Patients Suffering Age-Related Damage of the Yellow Spot of the Light-sensitive Tissue Layer in the EyeEUCTR2014-002168-34-CZDoc. MUDr. Petr Kolár, PhD, Ocní klinika FN Brno45
Active, not recruiting
Not Applicable
Study of Aflibercept as Maintenance Following Induction of Aflibercept in Combination with XELOX, as First-Line Treatment for Metastatic Colorectal Cancer PatientColorectal cancer metastaticMedDRA version: 16.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000858-22-ITSanofi-Aventis Groupe
Recruiting
Not Applicable
Multi-Center Study of Aflibercept Therapy for Neovascular Age-Related Macular Degeneration Using Trreat and Extend Strategyeovascular age-related macular degenerationJPRN-UMIN000016152Tokyo Women's Medical University200